4.6 Review

Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma

期刊

AMERICAN JOURNAL OF TRANSPLANTATION
卷 14, 期 10, 页码 2221-2227

出版社

WILEY
DOI: 10.1111/ajt.12923

关键词

Cancer/malignancy/neoplasia; clinical research/practice; liver disease: malignant; liver transplantation/hepatology; organ procurement and allocation

资金

  1. Swiss National Science Foundation [PP00P3_139021]
  2. Italian Association for Cancer Research (AIRC)
  3. Italian Ministry of Health
  4. Instituto de Salud Carlos III [PI11/01830]

向作者/读者索取更多资源

In some countries where the Model for End-Stage Liver Disease (MELD) score is used for graft allocation, selected patients with hepatocellular carcinoma (HCC) receive a fixed number of exception points at listing, and increasing priority on the list by accruing additional exception points at regular time intervals. This system originally aimed at balancing the risks of HCC patients of developing contraindications and of non-HCC patients of dying before transplantation, is not ideal because it appears to offer an advantage to HCC patients, regardless of tumor characteristics and response to loco-regional treatment. Scores modulated by HCC characteristics have been proposed. They are based on a more refined estimate of the risk of pretransplant drop-out or of the posttransplant transplant benefit expressed as the life-years gained for each graft. This review describes the newly proposed systems, and discusses their advantages and drawbacks. We believe that the current exception points allocation should be revised and that drop-out-equivalent or transplant benefit-equivalent models should be studied further. As with all policy changes, these should be done under close monitoring that allows subsequent revisions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据